Equities Analysts Issue Forecasts for KYMR Q2 Earnings

Key Points

• Analyst upgrades: Brookline Capital Markets raised its Q2 2026 EPS forecast to ($0.62) from ($0.97), and several firms have lifted targets, leaving a consensus Moderate Buy rating with a $118.70 consensus price target.
• Q1 beat: Kymera reported ($0.71) EPS vs. a ($0.89) consensus and revenue of $34.37 million versus $8.27 million estimated, a 55.5% year‑over‑year revenue increase.
• Pipeline progress: Kymera presented promising preclinical IBD data for KT‑579 showing activity comparable or superior to approved therapies, which could de‑risk the program if translated to humans.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Investment analysts at Brookline Capital Markets increased their Q2 2026 earnings per share (EPS) estimates for Kymera Therapeutics in a research note issued on Thursday, April 30th. Brookline Capital Markets analyst L. Cann now expects that the company will post earnings of ($0.62) per share for the quarter, up from their previous forecast of ($0.97). The consensus estimate for Kymera Therapeutics' current full-year earnings is ($3.49) per share. Brookline Capital Markets also issued estimates for Kymera Therapeutics' Q3 2026 earnings at ($1.11) EPS, Q4 2026 earnings at ($1.13) EPS, FY2026 earnings at ($3.57) EPS, FY2027 earnings at ($4.27) EPS, FY2028 earnings at ($4.73) EPS, FY2029 earnings at ($4.29) EPS and FY2030 earnings at ($4.68) EPS.

Other analysts also recently issued research reports about the stock. Stephens upped their price target on shares of Kymera Therapeutics from $95.00 to $100.00 and gave the company an "overweight" rating in a report on Monday, March 2nd. BTIG Research dropped their target price on Kymera Therapeutics from $138.00 to $134.00 and set a "buy" rating for the company in a research note on Thursday, February 26th. Jefferies Financial Group started coverage on Kymera Therapeutics in a research note on Monday, March 16th. They issued a "buy" rating and a $110.00 price target on the stock. Citigroup raised their price target on Kymera Therapeutics from $110.00 to $120.00 and gave the stock a "buy" rating in a research note on Monday, March 2nd. Finally, Morgan Stanley reissued an "overweight" rating and issued a $119.00 price target on shares of Kymera Therapeutics in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $118.70.

Kymera Therapeutics Trading Up 3.6%

NASDAQ KYMR opened at $83.59 on Tuesday. The business's 50 day moving average is $84.52 and its two-hundred day moving average is $76.47. Kymera Therapeutics has a 12-month low of $28.06 and a 12-month high of $103.00. The stock has a market capitalization of $6.88 billion, a price-to-earnings ratio of -23.41 and a beta of 2.06.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.18. The company had revenue of $34.37 million for the quarter, compared to analyst estimates of $8.27 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The firm's revenue was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.82) earnings per share.

Hedge Funds Weigh In On Kymera Therapeutics

A number of hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Kymera Therapeutics by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company's stock worth $849,000 after acquiring an additional 1,833 shares during the period. Millennium Management LLC boosted its position in Kymera Therapeutics by 340.4% during the 1st quarter. Millennium Management LLC now owns 510,480 shares of the company's stock worth $13,972,000 after acquiring an additional 394,562 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Kymera Therapeutics by 121.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company's stock worth $24,535,000 after acquiring an additional 491,737 shares during the period. Invesco Ltd. boosted its position in Kymera Therapeutics by 13.8% during the 2nd quarter. Invesco Ltd. now owns 47,884 shares of the company's stock worth $2,090,000 after acquiring an additional 5,809 shares during the period. Finally, Sei Investments Co. acquired a new stake in Kymera Therapeutics during the 2nd quarter worth about $265,000.

Insider Buying and Selling

In related news, insider Noah Goodman sold 1,347 shares of the company's stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $90.00, for a total transaction of $121,230.00. Following the completion of the transaction, the insider directly owned 50,195 shares in the company, valued at $4,517,550. This represents a 2.61% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock in a transaction on Wednesday, April 29th. The shares were sold at an average price of $81.18, for a total value of $2,435,400.00. Following the sale, the chief executive officer directly owned 666,195 shares in the company, valued at $54,081,710.10. The trade was a 4.31% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 380,734 shares of company stock worth $32,193,902. Company insiders own 16.01% of the company's stock.

Kymera Therapeutics News Summary

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Q1 results and follow-up analyst lift — Kymera beat Q1 revenue and EPS expectations, and coverage pieces note analysts are raising near-term estimates, supporting positive sentiment around execution and revenue growth. Kymera Therapeutics, Inc. NASDAQ: KYMR Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
• Positive Sentiment: Near‑term estimate upgrades from Brookline — The firm raised its Q2 2026 EPS forecast (improved from −$0.97 to −$0.62) and lifted FY2026 (from −$3.76 to −$3.57), suggesting the analyst sees better near‑term revenue or lower near‑term dilution/expense than previously modeled. This can be supportive for the stock if it signals improving fundamentals.
• Positive Sentiment: Promising preclinical data for KT‑579 — Kymera presented preclinical IBD results showing KT‑579 (oral IRF5 degrader) had activity comparable or superior to approved/clinically active therapies in models, which de‑risks the program and increases its clinical / commercial upside if translated to humans. Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week
• Neutral Sentiment: Corporate milestone / visibility event — Kymera rang the opening bell for its 10‑year anniversary (ceremonial, increases visibility but no direct operational impact). LIVE: Kymera Therapeutics, Inc. Rings the Opening Bell in Celebration of its 10-Year Anniversary
• Negative Sentiment: Some later‑period estimate cuts from Brookline — The same Brookline note lowered Q3 2026 (from −$1.01 to −$1.11) and Q4 2026 (to −$1.13 from −$0.84) and trimmed FY2027 expectations (worse from prior), indicating expectations for deeper/longer losses beyond the near term. That raises the possibility of continued dilution or heavy R&D spend, which can cap valuation until clinical readouts translate to clearer revenue prospects.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.